Skip to main content
The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology logoLink to The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology
. 2009 Aug 31;13(4):273–279. doi: 10.4196/kjpp.2009.13.4.273

Inhibition of β-amyloid1-40 Peptide Aggregation and Neurotoxicity by Citrate

Yong Hoon Park 1,*, Young-Jin Kim 2,*, Il Hong Son 1,2, Hyun Duk Yang 1,2,
PMCID: PMC2766705  PMID: 19885010

Abstract

The accumulation of β-amyloid (Aβ) aggregates is a characteristic of Alzheimer's disease (AD). Furthermore, these aggregates have neurotoxic effects on cells, and thus, molecules that inhibit Aβ aggregate formation could be valuable therapeutics for AD. It is well known that aggregation of Aβ depends on its hydrophobicity, and thus, in order to increase the hydrophilicity of Aβ, we considered using citrate, an anionic surfactant with three carboxylic acid groups. We hypothesized that citrate could reduce hydrophobicity and increase hydrophilicity of Aβ1-40 molecules via hydrophilic/electrostatic interactions. We found that citrate significantly inhibited Aβ1-40 aggregation and significantly protected SH-SY5Y cell line against Aβ1-40 aggregates-induced neurotoxicity. In details, we examined the effects of citrate on Aβ1-40 aggregation and on Aβ1-40 aggregates-induced cytotoxicity, cell viability, and apoptosis. Th-T assays showed that citrate significantly inhibited Aβ1-40 aggregation in a concentration-dependent manner (Th-T intensity: from 91.3% in 0.01 mM citrate to 82.1% in 1.0 mM citrate vs. 100.0% in Aβ1-40 alone). In cytotoxicity and viability assays, citrate reduced the toxicity of Aβ1-40 in a concentration-dependent manner, in which the cytotoxicity decreased from 107.5 to 102.3% as compared with Aβ1-40 aggregates alone treated cells (127.3%) and the cell viability increased from 84.6 to 93.8% as compared with the Aβ1-40 aggregates alone treated cells (65.3%). Furthermore, Hoechst 33342 staining showed that citrate (1.0 mM) suppressed Aβ1-40 aggregates-induced apoptosis in the cells. This study suggests that citrate can inhibit Aβ1-40 aggregation and protect neurons from the apoptotic effects of Aβ1-40 aggregates. Accordingly, our findings suggest that citrate administration should be viewed as a novel neuroprotective strategy for AD.

Keywords: Citrate, Alzheimer's disease, β-amyloid, Aggregation, Apoptosis

INTRODUCTION

The accumulation of β-amyloid (Aβ) peptides in senile plaque represents a major pathological change in the AD brain. Aβ is generated by the sequential proteolytic processing of amyloid precursor protein by β- and γ-secretases, and is known to promote pro-inflammatory responses and to activate neurotoxic pathways (Selkoe, 2001; Sisodia and St George-Hyslop, 2002; Pereira et al., 2005). The main therapeutic target in AD is Aβ, and devised anti-Aβ agents are known to primarily affect the production and accumulation of Aβ and to block toxic Aβ forms (Seiffert et al., 2000; Scarpini et al., 2003; Citron, 2004). Neuroprotective agents represent another drug class, and include antioxidants and anti-inflammatory agents, and neurorestorative agents and procedures represent another, and include nerve growth factors, transplantation, and stem-cell related therapy (McConnell and Riggs, 2005; Cummings et al., 2007). It has been reported that soluble Aβ oligomers are more toxic than monomeric and fibrillar Aβ forms (Rochet and Lansbury, 2000). For this reason, molecules that can inhibit Aβ aggregates formation could be of therapeutic value. The Aβ molecules are amphiphilic peptides that possess a hydrophilic region (N-terminal) and a hydrophobic region (C-terminal), and can self-assemble to form aggregates with various morphologies, such as, dimers, oligomers, filaments, protofibrils, and fibrils (Koh and Yang, 1990; Pike et al., 1993; Howlett et al., 1995; Seilheimer et al., 1999; Watanabe et al., 2001). Furthermore, Aβ aggregations are driven by intermolecular hydrophobic and electrostatic interactions (Jarrett et al., 1993; Wood et al., 1996b; Lazo et al., 2005; Luhrs et al., 2005; Khandogin and Brooks, 2007).

Hence, many materials have been studied to modulate Aβ aggregate formation. Small molecules like Congo red and small sulfonated anions have been shown to prevent Aβ aggregation or inhibit Aβ-related toxicity (Lorenzo and Yankner, 1994; Kisilevsky et al., 1995). Melatonin, nicotine, and estrogen have also been found to inhibit Aβ aggregation in a similar way (Salomon et al., 1996; Mook-Jung et al., 1997; Pappolla et al., 1998). A small number of surfactants have been found to inhibit Aβ aggregation by binding to its hydrophobic region, which is necessary for its self-assembly (Lomakin et al., 1996; Marcinowski et al., 1998; Wang et al., 2005). In particular, one of the various types of surfactants, citrate is a particularly appealing surfactant (Brus, 2008) because of its small size and high anionic charge density. Using Aβ peptide fragment 25-35 (Aβ25-35), we previously showed that citrate inhibits Aβ aggregation by fluorescence spectroscopy using thioflavin-T (Th-T) (Yang et al., 2008). Furthermore, Aβ25-35 peptides have the same aggregation and neurotoxic properties of full-length Aβ and have the experimental advantage of rapidly aggregating from solution (Pike et al., 1995). However, Aβ25-35 does not exist in the brain, which limits the clinical meaning results. Thus, in the present study, we used full length Aβ peptide (Aβ1-40), which constitutes about 90% of the most abundant cleaved form of larger amyloid precursor protein (APP), and which has been shown to have a toxic effect in the AD brain (Cao et al., 2007).

In this study, we investigated the inhibitory effect of citrate on Aβ1-40 aggregation and Aβ1-40 aggregates-induced cell damage and death in SH-SY5Y cell line.

METHODS

Synthetic peptides and citrate

1-40 TFA was purchased from rPeptide (Athens, Georgia, USA) and citrate was purchased from Sigma (Saint Louis, MO, USA), both were used without further purification.

Preparation of solutions

The stock solution of 0.5 mg/ml Aβ1-40 peptide was prepared by solubilizing lyophilized Aβ1-40 peptide by briefly vortexing in sterilized 0.6 mM NaOH solution for 5 min at room temperature and sonicating for 1 min at 4℃. The peptide stock solution was aliquoted and stored at -20℃. Citrate stock solution was neutralized to pH 7.4 and filtered through a 0.2 µm syringe filter, and it too was aliquoted and stored at -20℃.

Thioflavin-T (Th-T) fluorescence assays of Aβ1-40 aggregation

Experiments were carried out at pH 7.4 using reaction mixtures containing 80 µl phosphate buffer (5 mM final concentration) with 10 µl citrate (0.01, 0.1, and 1.0 mM final concentration) and 10 µl Aβ1-40 (20 µM final concentration). In details, samples containing Aβ1-40 alone or Aβ1-40 plus different concentrations of citrate, were used. All reactions were carried out at 37℃ for 6 days. The fluorescence intensities of Th-T dye, which represents the amount of Aβ1-40 aggregation, were measured using a PerkinElmer LS 55 Fluorescence Spectrometer (Waltham, Massachusetts, USA). 150 µl of 5 µM Th-T dye solution (in 50 mM sodium phosphate buffer, pH 6.0) was added to 20 µl of the Aβ1-40 reaction solutions. Fluorescence intensities of reaction mixtures were then measured at excitation and emission wavelengths of 450 and 490 nm, respectively.

SH-SY5Y cell culture and Aβ1-40-induced toxicity

SH-SY5Y cell line was sustained in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's 12 medium supplemented with 10% fetal bovine serum and antibiotic-antimycotic (10,000 U/ml penicillin G sodium, 10,000 µg/ml streptomycin sulfate and 25 µg/ml amphotericin B as Fungizone® in 0.85% saline) (Gibco, NY, USA) in a humidified 5% CO2/95% O2 atmosphere at 37℃. Culture media were changed every two days. For WST-1 and LDH assays, the cell line was plated at a density of 1×104 cells/well in 96-well plates and incubated for 24 h. They were then treated for 3 days with the solutions of Aβ1-40 (20 µM final concentration) in the absence or presence of different concentrations of citrate preincubated at 37℃ for 6 days.

Cell viability measurements

Cell viabilities were evaluated using WST-1 assays, which measure the combined activity of intramitochondrial and extramitochondrial dehydrogenases. Briefly, tetrazolium salts are cleaved by the dehydrogenases of viable cells to produce formazan which is detected spectrophotometrically. Dehydrogenase activities were assayed in collagen-coated 96 well-plates (density of 1×104 cells/well). The cells were exposed to the solutions of Aβ1-40 (20 µM) with/without various concentrations of citrate (0.01, 0.1 and 1.0 mM) preincubated for 6 days. After incubation for 3 days, media were removed and WST-1 reagent (diluted 1/10 with medium) was added. The cells were then incubated in a gassed atmosphere (5% CO2) for 3 hours. After vibrating plates, the changes in absorbance were measured using a Biotek Synergy 2 Multi-Detection Microplate Reader (Vermont, USA) at wavelength 450 nm.

Results are expressed as percentages of WST-1 reduced by assuming that the absorbance of (no-drug treated) control cell was 100%.

Measurement of cell damage

SH-SY5Y cell membrane integrities (cell damage) in culture were determined using a colorimetric lactate dehydrogenase (LDH) assay (TOX-7; Sigma-Aldrich Co, MO, USA) according to the manufacturer's instructions. This assay measures membrane integrity as function of the amount of cytoplasmic LDH released into culture medium. Briefly, the assay mixture was prepared by mixing equal amounts of LDH assay substrate, cofactor, and dye solutions. Culture media were added to LDH assay mixtures and incubated for 30 min at room temperature in the dark; the color reaction was stopped by adding 1 M HCl. Absorbances were measured at 490 nm using a Biotek Synergy 2 Multi-Detection Microplate Reader (Vermont, USA). Background correction was performed at 650 nm.

Identification of apoptotic cells after Hoechst 33342 nuclei staining

The nuclear morphologies of cells were studied using Hoechst 33342 dye (a cell-permeable DNA dye). Cells with homogeneously stained nuclei were considered viable, whereas the presence of chromatin condensation and/or fragmentation was taken to indicate apoptosis (Gschwind and Huber, 1995; Lizard et al., 1995). Hoechst 33342 was added to culture medium in a chamber slide (Lab-Tek Chamber Slide; NUNC) at a final concentration of 10 ug/ml and incubated for 1 h. The cells were then washed with phosphate buffered saline (PBS) containing 1% (w/v) paraformaldehyde, mounted on glass slides under coverslips using mounting solution (0.1 M citric acid:0.2 M NaH2PO4: glycerol=1:1:8), and stored in the dark for 30 min at 4℃. The cells were examined at 1,000×, and five random fields were chosen for each experimental condition. Hoechst 33342 stained images were obtained using a fluorescence photomicroscope (IX70; Olympus, Tokyo, Japan), with excitation centered at 350 nm and a 460 nm emission filter.

Statistical analyses

The results shown represent the means±standard deviations of three experiments. One-way analysis of variance (ANOVA) followed by Duncan's multiple-range test was used to determine whether means of treated groups were significantly different from that of (no-drug treated) control group or Aβ1-40 aggregates alone treated group. In all cases, p values of <0.05 were deemed significant.

RESULTS

Inhibitory effect of citrate on the formation of Aβ1-40 aggregates

In order to examine the concentration-dependency of the anti-aggregation effect of citrate on Aβ1-40, the concentration of Aβ1-40 was fixed at 20 µM and citrate was added at 0.01, 0.1, and 1.0 mM. After incubation for 6 days, Aβ aggregation was found to have been suppressed by citrate in a concentration-dependent manner (91.3±1.7%, 87.5±4.8% and 82.1±2.7% (at 0.01, 0.1, and 1.0 mM of citrate, respectively) vs. 100±3.4% (control)) (Fig. 1). In particular, at citrate concentrations of 0.1 and 1.0 mM, Aβ1-40 aggregation was significantly reduced (p<0.05).

Fig. 1.

Fig. 1

The effect of citrate on aggregate formation of Aβ1-40 was determined by Th-T fluorometric assays. Aβ1-40 at 20 µM was incubated with citrate at 0.01, 0.1, or 1.0 mM at 37℃ for 6 days. The fluorescence intensities of Aβ1-40 aggregate formation were measured using a spectrofluorometer. Results are means±SDs of three experiments. The asterisk (*) indicates a significant (p<0.05) difference between treatments with Aβ aggregates alone and Aβ plus citrate.

Protective effect of citrate on cell viability in Aβ1-40-treated cells

We analyzed the protective effect of citrate in the cells against the toxicity of exogenous Aβ1-40. When SH-SY5Y cell line was exposed to 20 µM of Aβ1-40 for 3 days, cell viability decreased as compared with that of (no-drug treated) control (65.3±5.2% vs. 100±3.6%). However, when cells were treated with the mixtures of Aβ1-40 plus citrate (0.01, 0.1, and 1.0 mM) preincubated for 6 days, the cell viabilities improved to 84.6±3.4%, 90.8±5.4% and 93.4±3.6%, respectively (Fig. 2). As shown in Fig. 2, viabilities in the mixtures of Aβ1-40 plus citrate treated groups were significantly greater than in Aβ1-40 aggregates alone treated group, and citrate was found to have a concentration-dependent protective effect (p<0.05).

Fig. 2.

Fig. 2

The effect of citrate on the viability of SH-SY5Y cell line. The cells were treated for 3 days with the solution of 20 µM Aβ1-40 with/without citrate preincubated at 37℃ for 6 days. Results are means±SDs of three experiments. The asterisk (*) indicates a significant (p<0.05) difference between treatment with Aβ alone and treatment with Aβ plus citrate.

Inhibitory effect of citrate on cell damage induced with Aβ1-40 aggregates

When exposed to 20 µM Aβ1-40 aggregates alone for 3 days, SH-SY5Y cell line showed the approx. 30% increase in LDH release, which is indicative of cytotoxic damage. However, when the cells were treated with Aβ1-40 plus citrate of 0.01, 0.1, or 1.0 mM final concentrations preincubated for 6 days, LDH releases of these were significantly reduced in a concentration-dependent manner as compared with Aβ1-40 aggregates alone treated group (107.5±3.4%, 103.9±4.6% and 102.3±2.3%, respectively, vs. 127.3±6.7%) (p<0.05) (Fig. 3), showing that citrate protected SH-SY5Y cell line from Aβ1-40 aggregates-induced cytotoxicity.

Fig. 3.

Fig. 3

The protective effect of citrate on Aβ1-40 aggregates-induced neuronal damage of SH-SY5Y cell line. The cells were treated for 3 days with the solution of 20 µM Aβ1-40 with/without citrate preincubated at 37℃ for 6 days. Results are means±SDs of three experiments. The asterisk (*) indicates a significant (p<0.05) difference between treatment with Aβ alone and treatment with Aβ plus citrate.

Inhibitory effect of citrate on apoptosis induced with Aβ1-40 aggregates

To study the cytoprotective effect of citrate on apoptosis induced with Aβ1-40 aggregates, nuclei of SH-SY5Y cells were stained with Hoechst 33342 for fluorescence microscopy. Hoechst 33342 is a DNA-binding dye that quantitatively stains the DNA of living cells. Briefly, the cells were treated with 20 µM of Aβ1-40 aggregates coincubated with/without 1.0 mM citrate for 6 days. Microscopic images (Fig. 4) showed that the (no-drug treated) control group showed the large intact nuclei but that Aβ1-40 aggregates alone treated cells displayed significant nuclear fragmentation and chromatin condensation (characteristic features of apoptosis). However, the cells treated with the mixtures of Aβ1-40 plus citrate had larger nuclei and showed weaker staining than Aβ1-40 aggregates alone treated group.

Fig. 4.

Fig. 4

Inhibitory effect of citrate on Aβ1-40-induced apoptosis. Apoptotic body formation was observed under a fluorescent microscope after Hoechst 33342 staining. Hoechst labeling shows (A) control (untreated cells), (B) increased nuclear condensation and fragmentation in 20 µM Aβ1-40 treated cells and (C) decreased nuclear condensation and fragmentation in cells treated with 20 µM Aβ1-40 plus 1.0 mM citrate preincubated for 6 days. The cells were labeled with 10 µg/ml Hoechst 33342 for 1 h after exposure to Aβ1-40 treatments for 3 days. Original magnification: ×1,000.

DISCUSSION

In this study to reduce Aβ aggregation, we added citrate, an anionic surfactant (Brus, 2008), to Aβ containing solutions and incubated for 6 days, and it was observed that Aβ1-40 aggregation was significantly suppressed. Furthermore, Aβ1-40 aggregates-induced cell damage was found to be significantly reduced and the viabilities of Aβ1-40 aggregates-treated cells were significantly improved by citrate.

Several studies have indicated that Aβ monomer must aggregate to polymeric or fibrillar form before it becomes toxic to neurons in culture (Pike et al., 1991), and soluble Aβ oligomers are known to be more toxic than monomeric or fibrillar Aβ (Rochet and Lansbury, 2000).

Amyloid aggregation, is a complex process that can be affected by various extrinsic or environmental factors, such as, pH, peptide concentration, solvent hydrophobicity, temperature, ionic strength, and metal ions (Halverson et al., 1990; Barrow and Zagorski, 1991; Bush et al., 1994; Snyder, 1994; Sabaté and Estelrich, 2005a). Hydrophobic and electrostatic interactions between Aβ molecules play pivotal roles in Aβ aggregation. According to Jarrett et al. (1993), the aggregation of Aβ peptides into amyloid fibrils is driven by hydrophobic interactions between highly apolar residues. Furthermore, it was found that replacing hydrophobic for hydrophilic residues in the internal hydrophobic region of Aβ can hinder aggregate formation, which suggested that Aβ aggregation is driven at least in part by hydrophobic interactions (Pike et al., 1995). In addition to hydrophobic forces, electrostatic interactions between residues also have a significant effect on the formation of Aβ aggregates (Lazo et al., 2005; Luhrs et al., 2005; Khandogin and Brooks, 2007). Several reports have concluded that positively charged Lys (28) within Aβ peptide plays a critical role in stabilizing the β-turn of Aβ, and thus, induces the growths of amyloid fibrils due intermolecular electrostatic interactions between negatively charged Glu (22) and Asp (23). In addition, at pH 7.4, both hydrophobic and electrostatic interactions are required to stabilize fibril structures during the aggregation of Aβ1-40 (Wood et al., 1996b). Under physiological conditions, human Aβ1-40 possesses several amino acid residues, namely, six cationic residues (three histidines, one arginine, and two lysines), six anionic residues (three aspartates, three glutamates) and 23 hydrophobic residues (three alanines, three phenylalanines, six glycines, six valines, two leucines, two isoleucines, and one methionine). Hence, human Aβ1-40 is amphiphilic, meaning that possess both hydrophobic and hydrophilic groups, like surfactants (Soreghan et al., 1994; Ji et al., 1995; Bokvist et al., 2004). Many reagents have been developed to modulate the aggregation of Aβ peptide (Pallitto et al., 1999; Lowe et al., 2001; Nowick et al., 2002; Ban et al., 2004), and, surfactants belong to one important category of the reagents.

In terms of anionic surfactants, several studies have investigated on the roles of sodium dodesyl sulfate (SDS) on the Aβ fibrillogenesis. Rangachari et al. found over a narrow range of SDS concentrations that SDS accelerated aggregation (Rangachari et al., 2006). Jeng et al. (2006) found that SDS could inhibit fibril formation by Aβ1-40 via the formation of a small peptide/SDS complex in aqueous solutions (Jeng et al., 2006), and this inhibitory effect is enhanced by SDS micelles when a larger SDS concentration is used.

Regarding cationic surfactants, Sabaté and Estelrich in a study of interactions between Aβ1-40 and three alkylammonium bromides that the surfactants promoted Aβ1-40 aggregation below the critical micelle concentration (CMC), but that the presence of micelles delayed aggregation (Sabaté and Estelrich, 2005b). Wood et al. (1996a) compared the effects of several surfactants on the aggregation of Aβ peptide and found that hexadecyl-N-methylpiperidinium (HMP) bromide selectively inhibited Aβ fibril formation (Wood et al., 1996a). Moreover, Sabaté et al. (2003) and Wang et al. (2005) have demonstrated that cationic surfactants inhibit Aβ fibril formation in a concentration-dependent manner (Sabaté et al., 2003; Sabaté and Estelrich, 2005b; Wang et al., 2005).

Studies on the interaction(s) between surfactant molecules and Aβ species and their aggregates have shown that the promotion and the stabilization of the α-helix secondary structure are highly correlated with the availability of charge on the surfactant surface, which suggests that electrostatic forces play a substantial role in the interaction between Aβ species and the surrounding aqueous medium and its constituents (Wang et al., 2005). Therefore, in order to suppress the aggregation of Aβ1-40, we selected citrate, an anionic surfactant which possesses three carboxylic acid groups (Brus, 2008).

Although the mechanisms responsible for the anti-aggregating effect of citrate have yet to be elucidated, we speculate that citrate inhibits Aβ aggregation by interacting with the amino acid residues of Aβ1-40. According to this suggestion, the anionic carboxyl groups of citrate ion-pair with cationic residues of Aβ, and leave its anionic charges intact, which may hinder its aggregation. Moreover, the hydrophobic parts of citrate could coat the hydrophobic parts of Aβ and convert these regions of Aβ into charged areas. As a consequence, this disruption of the dispositions of surface charges and hydrophobic regions of Aβ molecules may in turn disrupt the aggregation mechanism.

Based on the above possibility, we examined whether Aβ1-40 aggregation depends on the ratios of charges in the hydrophobic parts and hydrophilic parts of Aβ1-40 and charge on citrate. Human Aβ1-40 contains six cationic amino acids (three histidines, one arginine, and two lysines) and six anionic amino acids (three aspartates and three glutamates). In the experiment conducted, Aβ1-40 (20 µM) contained 120 µM cationic and 120 µM anionic amino acid residues, and thus, citrate (10 µM) contained less anionic groups than would be required to neutralize the cationic residues of Aβ1-40. We believe that one of three anionic groups of citrate binds to one cationic residues of Aβ1-40, and thus, leaves two anionic groups exposed to medium. If this were the case, citrate would increase the number of charges carried by Aβ1-40, improving the hydrophilicity and solubility of Aβ1-40. When citrate is present at 100 µM, its anionic groups are three-times that required to neutralize Aβ1-40 cationic residues. Thus, one third of the anionic groups of citrate could neutralize all Aβ1-40 cationic residues, and the free citrate anionic groups would increase the net charge and hydrophilicity of Aβ1-40. Hence, 100 µM citrate would be expected to increase the solubility of Aβ1-40, and 100 µM citrate would be expected to inhibit Aβ1-40 aggregation more than citrate at 10 µM, and similarly 1 mM citrate would be expected to have a greater effect. The observed concentration-dependent suppression of Aβ1-40 aggregation by citrate suggests that citrate significantly reduced Aβ1-40 aggregates-induced cytotoxicity and cell death via an apoptotic process in SH-SY5Y cells (Fig. 2, 4). Meanwhile, citrate has antioxidant activity (Puntel et al., 2007), which may partially contribute to inhibit Aβ1-40 aggregates-induced cell damage and apoptosis because Aβ1-40 aggregates-induced toxicities proceed via oxidative stress (Hensley et al., 1994).

Taken together, this study suggests that citrate has an inhibitory effect on the aggregation of Aβ1-40, which can protect neurons from Aβ1-40 aggregates-induced apoptosis. Our findings suggest that citrate should be viewed as a potential drug candidate for the treatment of AD.

ACKNOWLEDGEMENTS

The work was supported by a grant from Wonkwang University in 2009. The authors have no relevant financial interests to disclose.

ABBREVIATIONS

AD

Alzheimer's disease

Th-T

thioflavin-T

CMC

critical micelle concentration

HMP

hexadecyl-N-methylpiperidinium

References

  • 1.Ban T, Hoshino M, Takahashi S, Hamada D, Hasegawa K, Naiki H, Goto Y. Direct observation of Abeta amyloid fibril growth and inhibition. J Mol Biol. 2004;344:757–767. doi: 10.1016/j.jmb.2004.09.078. [DOI] [PubMed] [Google Scholar]
  • 2.Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science. 1991;253:179–182. doi: 10.1126/science.1853202. [DOI] [PubMed] [Google Scholar]
  • 3.Bokvist M, Lindström F, Watts A, Gröbner G. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol. 2004;335:1039–1049. doi: 10.1016/j.jmb.2003.11.046. [DOI] [PubMed] [Google Scholar]
  • 4.Brus L. Noble metal nanocrystals: plasmon electron transfer photochemistry and single-molecule raman spectroscopy. Acc Chem Res. 2008;41:1742–1749. doi: 10.1021/ar800121r. [DOI] [PubMed] [Google Scholar]
  • 5.Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science. 1994;265:1464–1467. doi: 10.1126/science.8073293. [DOI] [PubMed] [Google Scholar]
  • 6.Cao M, Han Y, Wang J, Wang Y. Modulation of fibrillogenesis of amyloid β (1-40) peptide with cationic gemini surfactant. J Phys Chem B. 2007;111:13436–13443. doi: 10.1021/jp075271b. [DOI] [PubMed] [Google Scholar]
  • 7.Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004;5:677–685. doi: 10.1038/nrn1495. [DOI] [PubMed] [Google Scholar]
  • 8.Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007;69:1622–1634. doi: 10.1212/01.wnl.0000295996.54210.69. [DOI] [PubMed] [Google Scholar]
  • 9.Gschwind M, Huber G. Apoptotic cell death induced by beta-amyloid 1-42 peptide is cell type dependent. J Neurochem. 1995;65:292–300. doi: 10.1046/j.1471-4159.1995.65010292.x. [DOI] [PubMed] [Google Scholar]
  • 10.Halverson K, Fraser PE, Kirschner DA, Lansbury PT., Jr Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry. 1990;29:2639–2644. doi: 10.1021/bi00463a003. [DOI] [PubMed] [Google Scholar]
  • 11.Hensley K, Carney JM, Mattson MP, Aksenova MV, Harris ME, Wu JF, Floyd RA, Butterfield DA. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA. 1994;91:3270–3274. doi: 10.1073/pnas.91.8.3270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Howlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R, Wood SJ, Camilleri P, Roberts GW. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 1995;4:23–32. doi: 10.1006/neur.1995.0003. [DOI] [PubMed] [Google Scholar]
  • 13.Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: implication for the pathogenesis of Alzheimer's disease. Biochemisty. 1993;32:4693–4697. doi: 10.1021/bi00069a001. [DOI] [PubMed] [Google Scholar]
  • 14.Jeng US, Lin TL, Lin JM, Ho DL. Contrast variation SANS for the solution structure of the β-amyloid peptide1-40 influenced by SDS surfactants. Physica B. 2006;385-386:865–867. [Google Scholar]
  • 15.Ji SR, Wu Y, Sui SF. Study of beta-amyloid peptide (Abeta40) insertion into phospholipid membranes using monolayer technique. Biochemistry (Mosc) 2002;67:1283–1288. doi: 10.1023/a:1021361607611. [DOI] [PubMed] [Google Scholar]
  • 16.Khandogin J, Brooks CL., III Linking folding with aggregation in Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci USA. 2007;104:16880–16885. doi: 10.1073/pnas.0703832104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med. 1995;1:143–148. doi: 10.1038/nm0295-143. [DOI] [PubMed] [Google Scholar]
  • 18.Koh JY, Yang LLY, Cotman CW. Beta-amyloid protein increases vulnerability of cultured neurons to excitotoxins. Brain Res. 1990;533:315–320. doi: 10.1016/0006-8993(90)91355-k. [DOI] [PubMed] [Google Scholar]
  • 19.Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB. On the nucleation of amyloid beta-protein monomer folding. Protein Sci. 2005;14:1581–1596. doi: 10.1110/ps.041292205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lizard G, Fournel S, Genestier L, Dhedin N, Chaput C, Flacher M, Mutin M, Panaye G, Revillard JP. Kinetics of plasma membrane and mitochondrial alterations in cells undergoing apoptosis. Cytometry. 1995;21:275–283. doi: 10.1002/cyto.990210308. [DOI] [PubMed] [Google Scholar]
  • 21.Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. On the nucleation and growth of amyloid beta-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA. 1996;93:1125–1129. doi: 10.1073/pnas.93.3.1125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA. 1994;91:12243–12247. doi: 10.1073/pnas.91.25.12243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry. 2001;40:7882–7889. doi: 10.1021/bi002734u. [DOI] [PubMed] [Google Scholar]
  • 24.Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, DobeliH, Schubert D, Riek R. 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc Natl Acad Sci USA. 2005;102:17342–17347. doi: 10.1073/pnas.0506723102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Marcinowski KJ, Shao H, Clancy EL, Zagorski MG. Solution structure model of residues 1-28 of the amyloid beta peptide when bound to micelles. J Am Chem Soc. 1998;120:11082–11091. [Google Scholar]
  • 26.McConnell S, Riggs J. Alzheimer's research: can it help save our nation's entitlement programs? Alzheimers Dement. 2005;1:84–86. doi: 10.1016/j.jalz.2005.06.005. [DOI] [PubMed] [Google Scholar]
  • 27.Mook-Jung I, Joo I, Sohn S, Kwon HJ, Huh K, Jung MW. Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension in B103 cells. Neurosci Lett. 1997;235:101–104. doi: 10.1016/s0304-3940(97)00632-0. [DOI] [PubMed] [Google Scholar]
  • 28.Nowick JS, Lam KS, Khasanova TV, Kemnitzer WE, Maitra S, Mee HT, Liu R. An unnatural amino acid that induces beta-sheetfolding and interaction in peptides. J Am Chem Soc. 2002;124:4972–4973. doi: 10.1021/ja025699i. [DOI] [PubMed] [Google Scholar]
  • 29.Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. Recognition sequence design for peptidyl modulators of betaamyloid aggregation and toxicity. Biochemistry. 1999;38:3570–3578. doi: 10.1021/bi982119e. [DOI] [PubMed] [Google Scholar]
  • 30.Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem. 1998;273:7185–7188. doi: 10.1074/jbc.273.13.7185. [DOI] [PubMed] [Google Scholar]
  • 31.Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord. 2005;4:383–403. doi: 10.2174/1568007054546117. [DOI] [PubMed] [Google Scholar]
  • 32.Pike CJ, burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993;13:1676–1687. doi: 10.1523/JNEUROSCI.13-04-01676.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol. 1991;207:367–368. doi: 10.1016/0922-4106(91)90014-9. [DOI] [PubMed] [Google Scholar]
  • 34.Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem. 1995;64:253–265. doi: 10.1046/j.1471-4159.1995.64010253.x. [DOI] [PubMed] [Google Scholar]
  • 35.Puntel RL, Roos DH, Grotto D, Garcia SC, Nogueira CW, Rocha JB. Antioxidant properties of Krebs cycle intermediates against malonate pro-oxidant activity in vitro: a comparative study using the colorimetric method and HPLC analysis to determine malondialdehyde in rat brain homogenates. Life Sci. 2007;81:51–62. doi: 10.1016/j.lfs.2007.04.023. [DOI] [PubMed] [Google Scholar]
  • 36.Rangachari V, Reed DK, Moore BD, Rosenberry TL. Secondary structure and interfacial aggregation of amyloid-beta (1-40) on sodium dodecyl sulfate micelles. Biochemistry. 2006;45:8639–8648. doi: 10.1021/bi060323t. [DOI] [PubMed] [Google Scholar]
  • 37.Rochet JC, Jr, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol. 2000;10:60–68. doi: 10.1016/s0959-440x(99)00049-4. [DOI] [PubMed] [Google Scholar]
  • 38.Sabaté R, Gallardo M, Estelrich J. An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid. Biopolymers. 2003;71:190–195. doi: 10.1002/bip.10441. [DOI] [PubMed] [Google Scholar]
  • 39.Sabaté R, Estelrich J. Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. J Phys Chem B. 2005a;109:11027–11032. doi: 10.1021/jp050716m. [DOI] [PubMed] [Google Scholar]
  • 40.Sabaté R, Estelrich J. Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. Langmuir. 2005b;21:6944–6949. doi: 10.1021/la050472x. [DOI] [PubMed] [Google Scholar]
  • 41.Salomon AR, Marcinowski KJ, Friedland RW, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry. 1996;35:13568–13578. doi: 10.1021/bi9617264. [DOI] [PubMed] [Google Scholar]
  • 42.Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003;2:539–547. doi: 10.1016/s1474-4422(03)00502-7. [DOI] [PubMed] [Google Scholar]
  • 43.Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem. 2000;275:34086–34091. doi: 10.1074/jbc.M005430200. [DOI] [PubMed] [Google Scholar]
  • 44.Seilheimer B, Bohrmann B, Bondolfi L, Müller F, Stüber D, Döbeli H. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol. 1997;119:59–71. doi: 10.1006/jsbi.1997.3859. [DOI] [PubMed] [Google Scholar]
  • 45.Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766. doi: 10.1152/physrev.2001.81.2.741. [DOI] [PubMed] [Google Scholar]
  • 46.Sisodia SS, St George-Hyslop PH. Gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci. 2002;3:281–290. doi: 10.1038/nrn785. [DOI] [PubMed] [Google Scholar]
  • 47.Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid-beta aggregation: selective inhibition of aggregation in mixturesof amyloid with different chain lengths. Biophys J. 1994;67:1216–1228. doi: 10.1016/S0006-3495(94)80591-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Soreghan B, Kosmoski J, Glabe C. Surfactant properties of Alzheimer's Abeta peptides and the mechanism of amyloid aggregation. J Biol Chem. 1994;269:28551–28554. [PubMed] [Google Scholar]
  • 49.Wang SS, Chen YT, Chou SW. Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta. 2005;1741:307–313. doi: 10.1016/j.bbadis.2005.05.004. [DOI] [PubMed] [Google Scholar]
  • 50.Watanabe K, Segawa T, Nakamura K, Kodaka M, Konakahara T, Okuno H. Identification of the molecular-interaction site of amyloid beta peptide by using a fluorescence assay. J Pept Res. 2001;58:342–346. doi: 10.1034/j.1399-3011.2001.00920.x. [DOI] [PubMed] [Google Scholar]
  • 51.Wood SJ, MacKenzie L, Maleeff B, Hurle MR, Wetzel R. Selectiveinhibition of Abeta fibril formation. J Biol Chem. 1996a;271:4086–4092. doi: 10.1074/jbc.271.8.4086. [DOI] [PubMed] [Google Scholar]
  • 52.Wood SJ, Maleeff B, Hart T, Wetzel R. Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. J Mol Biol. 1996b;256:870–877. doi: 10.1006/jmbi.1996.0133. [DOI] [PubMed] [Google Scholar]
  • 53.Yang HD, Son IH, Lee SS, Park YH. Protective effect of citrate against Aβ-induced neurotoxicity in PC12 cells. Mol Cell Toxicol. 2008;4:157–163. [Google Scholar]
  • 54.Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 1996;16:921–932. doi: 10.1016/s0896-6273(00)80115-4. [DOI] [PubMed] [Google Scholar]

Articles from The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology are provided here courtesy of Korean Physiological Society and Korean Society of Pharmacology

RESOURCES